DR HERRING PUBLISHES LANDMARK ADVANCES IN THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH)
In the current issue of Hepatology, the official journal of the American Association for the Study of Liver Disease, Dr. Herring releases new data on the most efficacious treatment of NASH. NASH, known as as the Silent Killer, is the second most common cause of liver transplantation in the US. Those who are not transplanted die. NASH is also the major cause of liver cancer in the US. The medications in the summary chart below, as well as other drugs for NASH are available from Dr. Herring now.”
DR. ROBERT W.HERRING, JR. ,PUBLISHED NEW CUTTING EDGE STUDY DATA RELATED TO THE TREAMTENT OF GENOTYPE 1 HEPATITIS C.
Published in Hepatology, July 2014, was “ALL ORAL COMBINATION OF LEDIPASVIR,VEDROPREVIR, TEGOBUVIR, AND RIBAVIRIN IN TREATMENT-NAÏVE PATIENTS WITH GENOTYPE 1 HCV INFECTION.”Due to the importance of the findings, the report was published in July 2014, by the world’s most widely read journal for liver disease and research, Hepatology. Hepatology is the official journal of the American Association for the Study of Liver Disease, the largest professional organization for liver doctors, with over 5000 members worldwide.Dr. Robert W. Herring, Jr. ,published in Hepatology last year as well.
Earlier this year, Dr. Herring published two other articles regarding his hepatitis C research, in the prestigious, New England Journal of Medicine. He published in the New England Journal of Medicine last year as well. Additionally, he has published findings in two of the widely read journals, The Journal of Clinical Gastroenterology and Gastroenterology.
Dr. Herring did his research training at John Hopkins and has over 30 years of research experience. Dr. Herring’s clinical research as it relates to HCV and other diseases of the liver,has lead him to be a leader in PILL ONLY TREATMENT OF HEPATITIS C in relation to this field of study. To learn more regarding this new drug treatment, please call Christy Swope, RN at 615-835-4738.
To review Dr. Herrings latest genotype 1 article please follow the hotlink www.ncbi.nlm.nih.gov
Additional articles that Dr. Herring has authored and co-authored are listed below, please click on the article to review the abstract of that study
- All-oral combination of ledipasvir, vedroprevir,tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection
- PROPEL: A Randomized Trail of Mericitabine Plus Peginterferon Alpha-2a Therapy in Treatment-Naïve HCV Genotype ¼ Patients
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatement options
- Safety and Tolerance of Oral 5-ASA (Asacol) in the treatment of Ulcerative Colitis and Crohn’s Disease: Results of the US Multicenter Open-Label Study
- Balapiravir Plus Pegiterferon alfa-2a (40KD) and Ribavirin for the treatment of Chronic Hepatitis C Genotype 1: Randomized Double-Blind, Placebo-Controlled Phase 2 Study
- Racial differences in response rates to consensus interferon in HCV infected patient’s naïve to previous therapy
- Oral 5-ASA (Asacol) in the treatment of Mild to Moderate Ulcerative Colitis (UC): The Nashville Experience
- Effect of acute alcohol administration on erythrocyte aldehyde dehydrogenase activity in man
Miracle drugs carry big price tags
Hepatitis C drug’s
$1000 cost worries
By Tom Wilemon
Sovaldi is a pill to take sitting down at the dinner table. Costing $1,000 a dose, losing one is akin to dropping a diamond down the drain.
At a time when federal and state governments are trying to rein in health care spending through myriad initiatives, the high cost of new blockbuster drugs such as Sovaldi and specialized cancer treatments could torpedo those efforts.
But this new hepatitis C treatment is a lifesaver for people like Barry Morrow of Clarksville because it cures the virus infection when other drugs have failed. Morrow tried to beat hepatitis C in 2008, taking the only treatments available at that time. His viral load never budged.
After Sovaldi became available, his doctor prescribed the new drug along with the same regimen he took before. This time, no virus was detected after only four weeks of treatment. Morrow stayed on track for the full 12-week course, taking his last Sovaldi on May 23.
Last week, a followup blood test confirmed he was free of hepatitis C – in his case a particularly stubborn strain of the virus.
"I don’t have words to describe how I feel,” Morrow said.
Grateful could be one word. Because he is a U.S. Navy retiree, his treatments were covered by TRICARE Prime.
Sovaldi has become the symbol for exorbitant pharmaceuticals. Its maker, Gilead Science Inc., defends the price, saying it “reflects the value of the medicine” and that its cost is “comparable to the previous standard of care regimen” even though it works faster and better with fewer side effects.
Dr. Robert W. Herring Jr., a Nashville liver specialist, doesn’t spend too much time worrying about the macroeconomic conditions of the pharmaceutical market. He just wants to make sure his patients get the medicines they need.
“I have written so far about 60 prescriptions for Sovaldi,” Herring said. “They have all been approved except for TennCare patients.”
TennCare will approve Sovaldi when criteria are met. They include a biopsy or diagnostic imagery that indicates liver damage.
“I think the biggest problem with TennCare right now is that they do not want to use Sovaldi on people unless they have very advanced disease,” Herring said.
Here are the recent publications by Dr. Herring in many of the world’s most prestigious medical journals. Quality Medical Research and its patients are advancing the frontiers of medical science.
- Nezam Afdhal, M.D., K. Rajender Reddy, M.D., David R. Nelson, M.D., Eric Lawitz, M.D., Stuart C. Gordon, M.D., Eugene Schiff, M.D., Ronald Nahass, M.D., Reem Ghalib, M.D., Norman Gitlin, M.D., Robert Herring, M.D., Jacob Lalezari, M.D., Ziad H. Younes, M.D., Paul J. Pockros, M.D., Adrian M. Di Bisceglie, M.D., Sanjeev Arora, M.D., G. Mani Subramanian, M.D., Ph.D., Yanni Zhu, Ph.D., Hadas Dvory-Sobol, Ph.D., Jenny C. Yang, Pharm.D., Phillip S. Pang, M.D., Ph.D., William T. Symonds, Pharm.D., John G. McHutchison, M.D., Andrew J. Muir, M.D., Mark Sulkowski, M.D., and Paul Kwo, M.D. for the ION-2 Investigators.; “Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection” The New England Journal of Medicine, April 12, 2014: DOI: 10.1056/NEJMoa1316366
- Kris V. Kowdley, M.D., Stuart C. Gordon, M.D., K. Rajender Reddy, M.D., Lorenzo Rossaro, M.D., David E. Bernstein, M.D., Eric Lawitz, M.D., Mitchell L. Shiffman, M.D., Eugene Schiff, M.D., Reem Ghalib, M.D., Michael Ryan, M.D., Vinod Rustgi, M.D., Mario Chojkier, M.D., Robert Herring, M.D., Adrian M. Di Bisceglie, M.D., Paul J. Pockros, M.D., G. Mani Subramanian, M.D., Ph.D., Di An, Ph.D., Evguenia Svarovskaia, Ph.D., Robert H. Hyland, D.Phil., Phillip S. Pang, M.D., Ph.D., William T. Symonds, Pharm.D., John G. McHutchison, M.D., Andrew J. Muir, M.D., David Pound, M.D., and Michael W. Fried, M.D. for the ION-3 Investigators; “Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis” The New England Journal of Medicine, April 11, 2014: DOI: 10.1056/NEJMoa1402355
- Pruitt, R.E., M.D., Gremillion, Daniel, M.D., Herring, Robert W., Jr., M.D., Bailey, Allan, M.D., Faust, Thomas W., M.D., Long, Karen M., RN, MSN, CFNP. “Safety and Tolerance of Oral 5-ASA (Asacol) in the Treatment of Ulcerative Colitis and Crohn’s Disease: Results of the US Multicenter Open-Label Study.” Gastroenterology, 100: A 241, 1991.
- Gaglio PJ, Rodrigues-Torres M, Herring R, Anand B, Box T, Rabinovitz M, Brown RS: Infergen Study Group. “Racial differences in response rates to consensus interferon in HCV infected patient’s naïve to previous therapy”. Journal of Clinical Gastroenterology. 38(7):599-604, Aug 2004.
- I. Jacobson, E. Lawitz, J. Lalezari, I. Crespo, M. Davis, T. Hassanein, M. DeMicco, S. Arora, N. Gitlin, R. Herring, D.R. Nelson, J.K. Anderson, R.H. Hyland. “GS-7977 400 mg QD Safety and Tolerability in the Over 500 Patients Treated for 12 Weeks”. Poster Presentation. 47th Annual European Association for the Study of the Liver, April, 2012.
- M. Sulkowski, M. Rodriguez-Torres, E. Lawitz, M. Shiffman, S. Pol, R. Herring, J.G. McHutchison, P.S. Pang, K.A. Wong, B. Massetto, Y. Zhu, D.M. Brainerd, D. Wyles, F. Habersetzer. “Interim Sustained Virologic Response Rates in Treatment-Naïve HCV Genotype 1a and 1b Patients Treated for 12 or 24 Weeks with an Interferon-Free All-Oral Quad Regimen”. Poster Presentation. 47th Annual European Association for the Study of the Liver, April, 2012.
- Andrew J. Muir, Robert Herring, Jr., Aasim Sheikh, Michael Ryan, VinodRustgi, Viktor Ankoma-Sey, Joanne Fabrycki, James Freddo, James Hui, Mingjun Huang, Dharaben Patel, Lisa Robarge, Heather Robison, Guangwei Yang, Yongsen Zhao, Milind Deshpande, Hetal S. Kocinksy, Robert Brennan. “A Single Direct-Acting Anti-Viral Agent, ACH-3102, in Combination with Ribavirin is Able to Achieve SVR8 in Subjects with Genotype 1b Chronic Hepatitis C Infection”. Abstract, Annual Meeting, 2013, European Association for the Study of the Liver.
- Jacobson IM, Gordon SC, Kowdley KV, Yoshidia EM, Rodriques-Torres M, SulkowskiMS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Lianko S, Nelson DR, George J, Leggett B, Pianko S, Thompson A, Elkashab M, Ramji A, Swain M, Willems B, Yoshida E, Gane E, Stedman C, Afdhal N, Aggarwal A, Bank L, Beavers K, Bennett M, Chung R, Davis M, Elion R, Etzkorn K, Everson G, Freilich B, Galambos M, Gordon S, Hassanein T, Herring R Jr, Hinestrosa F, Jacobson I, Kowdley K, Kugelmas M, Lalezari J, Lawitz E, Martorell C, Mills A, Morelli G, Nahass R, Nyberg A, Perumalswami P, Poleynard G, Reddy KR, Roderiguez-Torres M, Ruane P, Rustgi V, Ryan M, Saag M, Schiff E, Sepe T, Sheikh A, Shiffman M, Smith C, Sulkowski M, Wyles D, Younes Z, Younossi Z ; POSITRON Study, FUSION Study, “Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options”. New England Journal of Medicine 2013 May 16; 368(20):1867-77.
- Wedemeyer, H., Jensen, D., Herring, Jr., R., Ferenci, P., Mang-Ming, M., Zeuzem, S., Rodriguez-Torres, M., Bzowej, N., Pockros, P., Vierling, J., Ipe, D., Munson, M.L., Chen, Y-C., Thommes, J. “*PROPEL: A Randomized Trial of Mericitabine Plus Peginterferon Alpha-2a Therapy in Treatment-Naïve HCV Genotype 1/4 Patients” Hepatology, August, 2013.
- Eric Yoshida, Mark Sulkowski, Edward Gane, Robert Herring, Julia Ma, John McNally, Luisa Stamm, Diana Brainard, William Symonds, John McHutchison, Kimberly Beavers, Ira Jacobson, K. Rajender Reddy, Eric Lawitz . “The Concordance Between SVR4, SVR12, and SVR24 in Patients With Chronic HCV Infection Who Received Treatment With Sofosburvir (SOF) in Phase 3 Clinical Trials”. Poster Presentation. American Association for the Study of Liver Diseases, Annual Meeting, 2013.
- Wyles DL, Rodriguez-Torres M, Lawitz E, Shiffman ML, Pol S, Herring RW, Massetto B, Kanwar B, Trenkle JD, Pang PS, Zhu Y, Mo H, Brainard DM, Subramanian GM, McHutchison JG, Habersetzer F, Sulkowski MS “All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naive Patients with Genotype 1 HCV”. Hepatology, February 2014